BridgeBio director trades shares after option exercise
BridgeBio Pharma director Jennifer E. Cook reported option exercises and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma director Jennifer E. Cook reported option exercises and related share sales. On June 15, 2026, she exercised options to acquire 83,088 shares of common stock at exercise prices of $8.45 and $16.75 per share.
On the same date, she sold 90,240 shares of common stock in open-market transactions at weighted average prices of $66.6153 and $67.1425 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 16, 2026. Following these transactions, she directly owned 8,092 shares of BridgeBio Pharma common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Cook Jennifer E.
Role
Director
Sold
90,240 shs ($6.01M)
Approx. gross sale proceeds
$6.01M
Approx. exercise cost
$845K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 65,921 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 17,167 | $0.00 | $0.00 |
| Exercise | Common Stock | 65,921 | $8.45 | $557K |
| Exercise | Common Stock | 17,167 | $16.75 | $288K |
| Sale | Common Stock | 88,737 | $66.6153 | $5.91M |
| Sale | Common Stock | 1,503 | $67.1425 | $101K |
Holdings After Transaction:
Stock Option (Right to Buy) — 73,334 contracts (Direct);
Common Stock — 6,589 shares (Direct)
Footnotes (5)
- F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
- F2. Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3. Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F4. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
- F5. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Key Figures
Shares sold: 90,240 shares
Sale price tranche 1: $66.6153 per share
Sale price tranche 2: $67.1425 per share
+3 more
6 metrics
Shares sold
90,240 shares
Open-market sales on June 15, 2026
Sale price tranche 1
$66.6153 per share
Weighted average sale price for 88,737 shares
Sale price tranche 2
$67.1425 per share
Weighted average sale price for 1,503 shares
Options exercised at $8.45
65,921 shares
Stock options exercised into common stock
Options exercised at $16.75
17,167 shares
Stock options exercised into common stock
Post-transaction holdings
8,092 shares
Common stock held directly after transactions
Key Terms
Rule 10b5-1 sales plan, weighted average sale price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted..."
weighted average sale price financial
"Represents the weighted average sale price of the shares sold from $66.10 to $67.095..."
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"1/3rd of the shares underlying the option will vest on June 22, 2023..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BridgeBio Pharma (BBIO) director Jennifer Cook report in this Form 4?
Jennifer Cook reported exercising stock options for 83,088 BridgeBio Pharma shares and selling 90,240 shares in open-market trades. The filing shows these were routine compensation-related option exercises paired with sales on the same date.
Were Jennifer Cook’s BridgeBio Pharma (BBIO) stock sales under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state the transactions were executed under a Rule 10b5-1 sales plan adopted on March 16, 2026. Such pre-arranged plans automate trading and can reduce the significance of trade timing as a discretionary signal.
What stock options did Jennifer Cook exercise in BridgeBio Pharma (BBIO)?
She exercised options covering 65,921 shares at a $8.45 exercise price and 17,167 shares at a $16.75 exercise price. These exercises converted derivative option positions into BridgeBio Pharma common stock before the related open-market sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates